Anavex Life Sciences Analyst Ratings
Anavex Life Sciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/28/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
08/08/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
07/20/2023 | — | HC Wainwright & Co. | Reiterates | Buy → Buy | |
06/29/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
05/02/2023 | 750.39% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
03/31/2023 | 750.39% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
02/09/2023 | 340.94% | BTIG | $35 → $28 | Maintains | Buy |
02/09/2023 | 687.4% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
02/06/2023 | 687.4% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
01/03/2023 | 687.4% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
12/06/2022 | 73.23% | Cantor Fitzgerald | $16 → $11 | Downgrades | Overweight → Neutral |
06/23/2022 | 529.92% | Berenberg | → $40 | Initiates Coverage On | → Buy |
02/02/2022 | 561.42% | HC Wainwright & Co. | $39 → $42 | Maintains | Buy |
09/23/2021 | 451.18% | BTIG | → $35 | Initiates Coverage On | → Buy |
06/28/2021 | 514.17% | HC Wainwright & Co. | $25 → $39 | Maintains | Buy |
06/15/2021 | 293.7% | HC Wainwright & Co. | $17 → $25 | Maintains | Buy |
02/23/2021 | 293.7% | Cantor Fitzgerald | $10 → $25 | Reiterates | → Overweight |
12/16/2020 | 167.72% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
10/21/2020 | 120.47% | HC Wainwright & Co. | $12 → $14 | Maintains | Buy |
09/28/2020 | 88.98% | Ladenburg Thalmann | → $12 | Initiates Coverage On | → Buy |
03/16/2020 | 88.98% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
07/24/2019 | 151.97% | Dawson James | → $16 | Initiates Coverage On | → Buy |
06/18/2019 | 57.48% | Janney Montgomery Scott | → $10 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/28/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | 购买 → 购买 |
08/08/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | 购买 → 购买 |
07/20/2023 | — | HC Wainwright & Co. | 重申 | 购买 → 购买 | |
06/29/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | 购买 → 购买 |
05/02/2023 | 750.39% | HC Wainwright & Co. | → 54 美元 | 重申 | → 购买 |
03/31/2023 | 750.39% | HC Wainwright & Co. | 50 美元 → 54 美元 | 维护 | 买 |
02/09/2023 | 340.94% | BTIG | 35 美元 → 28 美元 | 维护 | 买 |
02/09/2023 | 687.4% | HC Wainwright & Co. | → 50 美元 | 重申 | → 购买 |
02/06/2023 | 687.4% | HC Wainwright & Co. | → 50 美元 | 重申 | → 购买 |
01/03/2023 | 687.4% | HC Wainwright & Co. | 42 美元 → 50 美元 | 维护 | 买 |
12/06/2022 | 73.23% | 坎托·菲茨杰拉德 | 16 美元 → 11 美元 | 降级 | 超重 → 中性 |
06/23/2022 | 529.92% | 贝伦贝格 | → 40 美元 | 启动覆盖范围开启 | → 购买 |
02/02/2022 | 561.42% | HC Wainwright & Co. | 39 美元 → 42 美元 | 维护 | 买 |
2021 年 9 月 23 日 | 451.18% | BTIG | → 35 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 6 月 28 日 | 514.17% | HC Wainwright & Co. | 25 美元 → 39 美元 | 维护 | 买 |
06/15/2021 | 293.7% | HC Wainwright & Co. | 17 美元 → 25 美元 | 维护 | 买 |
2021 年 2 月 23 日 | 293.7% | 坎托·菲茨杰拉德 | 10 美元 → 25 美元 | 重申 | → 超重 |
2020 年 12 月 16 日 | 167.72% | HC Wainwright & Co. | 14 美元 → 17 美元 | 维护 | 买 |
10/21/2020 | 120.47% | HC Wainwright & Co. | 12 美元 → 14 美元 | 维护 | 买 |
09/28/2020 | 88.98% | 拉登堡塔尔曼 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
03/16/2020 | 88.98% | HC Wainwright & Co. | → 12 美元 | 启动覆盖范围开启 | → 购买 |
07/24/2019 | 151.97% | 道森·詹姆斯 | → 16 美元 | 启动覆盖范围开启 | → 购买 |
06/18/2019 | 57.48% | 詹尼蒙哥马利斯科特 | → 10 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Anavex Life Sciences (AVXL)?
Anavex Life Sciences (AVXL) 的目标价格是多少?
The latest price target for Anavex Life Sciences (NASDAQ: AVXL) was reported by HC Wainwright & Co. on November 28, 2023. The analyst firm set a price target for $54.00 expecting AVXL to rise to within 12 months (a possible 750.39% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月28日公布了Anavex Life Sciences(纳斯达克股票代码:AVXL)的最新目标股价。该分析公司将目标股价定为54.00美元,预计AVXL将在12个月内上涨至750.39%(可能上涨750.39%)。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Anavex Life Sciences (AVXL)?
Anavex Life Sciences (AVXL) 的最新分析师评级是多少?
The latest analyst rating for Anavex Life Sciences (NASDAQ: AVXL) was provided by HC Wainwright & Co., and Anavex Life Sciences reiterated their buy rating.
Anavex Life Sciences(纳斯达克股票代码:AVXL)的最新分析师评级由HC Wainwright & Co. 提供,Anavex Life Sciences 重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Anavex Life Sciences (AVXL)?
Anavex Life Sciences(AVXL)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anavex Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anavex Life Sciences was filed on November 28, 2023 so you should expect the next rating to be made available sometime around November 28, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Anavex Life Sciences的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Anavex Life Sciences的最新评级是在2023年11月28日发布的,因此您应该预计下一个评级将在2024年11月28日左右公布。
Is the Analyst Rating Anavex Life Sciences (AVXL) correct?
分析师对 Anavex Life Sciences (AVXL) 的评级是否正确?
While ratings are subjective and will change, the latest Anavex Life Sciences (AVXL) rating was a reiterated with a price target of $0.00 to $54.00. The current price Anavex Life Sciences (AVXL) is trading at is $6.35, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Anavex Life Sciences(AVXL)评级得到了重申,目标股价为0.00美元至54.00美元。Anavex Life Sciences(AVXL)目前的交易价格为6.35美元,在分析师的预测区间内。